Long-term safety study of acoramidis for newly diagnosed ATTR-CM
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism, Mental health clinical trials.
This study looks at the long-term safety of the study drug acoramidis for people living with a heart condition called ATTR-CM. It may help doctors understand the long-term effects and benefits of this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished the earlier AG10-501 study within the last 2 months.
- You must have a condition called ATTR-CM (a type of heart disease caused by a protein buildup).
- You cannot have a history of certain other conditions, such as AL amyloidosis or other non-TTR amyloid types.
- You cannot have advanced kidney disease (stage IV or V).
- You cannot have had an organ or tissue transplant (other than a cornea).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
This study follows patients with a specific type of heart amyloidosis (wild-type ATTR) who are taking or could start the drug tafamidis. It aims to learn more about how the condition and treatment affect people over time.
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
This trial studies whether a structured exercise training program is safe and helpful for people with transthyretin (ATTR) cardiac amyloidosis. It may help improve fitness and daily functioning, and it may also compare groups for specific eligibility needs.
This study is testing a medication called acoramidis for people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). It aims to see how well the treatment works in a real-world setting in France.
Hear when a new Amyloidosis, Familial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.